Showing 361 - 380 results of 901 for search '"Alzheimers"', query time: 0.08s Refine Results
  1. 361

    Young Coconut Juice Reduces Some Histopathological Changes Associated with Alzheimer’s Disease through the Modulation of Estrogen Receptors in Orchidectomized Rat Brains by Tatcha Balit, Mosaad A. Abdel-Wahhab, Nisaudah Radenahmad

    Published 2019-01-01
    “…This study aimed to evaluate the protective role of young coconut juice (YCJ) against the pathological changes in Alzheimer’s disease (AD) in orchidectomized (orx) rats. …”
    Get full text
    Article
  2. 362

    APOE4 and infectious diseases jointly contribute to brain glucose hypometabolism, a biomarker of Alzheimer's pathology: New findings from the ADNI. by Aravind Lathika Rajendrakumar, Konstantin G Arbeev, Olivia Bagley, Matt Duan, Anatoliy I Yashin, Svetlana Ukraintseva, Alzheimer’s Disease Neuroimaging Initiative

    Published 2025-01-01
    “…<h4>Background</h4>Impaired brain glucose metabolism is a preclinical feature of neurodegenerative diseases such as Alzheimer's disease (AD). Infections may promote AD-related pathology. …”
    Get full text
    Article
  3. 363
  4. 364
  5. 365
  6. 366
  7. 367
  8. 368

    Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis by Jinwang Ye, Suyue Zhong, Huali Wan, Xing Guo, Xuanbao Yao, Qiong Liu, Liming Chen, Jian-Zhi Wang, Shifeng Xiao

    Published 2025-01-01
    “…Abstract Background Astrocytes, the most abundant glial cell type in the brain, will convert into the reactive state in response to proteotoxic stress such as tau accumulation, a characteristic feature of Alzheimer's disease (AD) and other tauopathies. The formation of reactive astrocytes is partially attributed to the disruption of autophagy lysosomal signaling, and inhibiting of some histone deacetylases (HDACs) has been demonstrated to reduce the molecular and functional characteristics of reactive astrocytes. …”
    Get full text
    Article
  9. 369
  10. 370
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376

    Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer’s disease by administration through an intranasal route by Anne-Claire Groo, Thomas Curel, Aurélie Malzert-Fréon, Line Séguy, Ophélie Bento, Sophie Corvaisier, Thomas Culerier, Romain Legrand, Noëlle Callizot, Alexandre Henriques, Georgia Culley, Sylvie Claeysen, Christophe Rochais, Patrick Dallemagne

    Published 2025-02-01
    “…Inhibition of the latter, as well as activation of β2-AR, are of interest for the treatment of Alzheimer’s disease (AD). Combining these two activities, bambuterol could express a good clinical efficacy against AD. …”
    Get full text
    Article
  17. 377

    Targeting Soluble Amyloid Oligomers in Alzheimer’s Disease: A Hypothetical Model Study Comparing Intrathecal Pseudodelivery of mAbs Against Intravenous Administration by Manuel Menendez-Gonzalez

    Published 2025-01-01
    “…Background/Objective: Neurotoxic soluble amyloid-β (Aβ) oligomers are key drivers of Alzheimer’s pathology, with evidence suggesting that early targeting of these soluble forms may slow disease progression. …”
    Get full text
    Article
  18. 378

    Effects of Simultaneously Applied Short-Term Transcutaneous Electrical Nerve Stimulation and Tactile Stimulation on Memory and Affective Behaviour of Patients with Probable Alzheimer’s Disease by E. Scherder, A. Bouma, L. Steen

    Published 1995-01-01
    “…In previous studies beneficial effects of peripheral electrical or tactile nerve stimulation were observed on memory and affective behaviour in patients with probable Alzheimer's disease. In the present study, it was investigated whether electrical and tactile stimulation applied simultaneously to Alzheimer patients would exceed the effects which were observed following treatment by each type of stimulation separately. …”
    Get full text
    Article
  19. 379

    Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer's disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitors. by Fatima Zahra Guerguer, Bouchra Rossafi, Oussama Abchir, Yasir S Raouf, Dhabya Bakhit Albalushi, Abdelouahid Samadi, Samir Chtita

    Published 2025-01-01
    “…Cognitive dysfunction in Alzheimer's disease results from a complex interplay of various pathological processes, including the dysregulation of key enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase B (MAO-B). …”
    Get full text
    Article
  20. 380

    Advancing Alzheimer’s disease risk prediction: development and validation of a machine learning-based preclinical screening model in a cross-sectional study by Yanfei Chen, Bing Wang, Yankai Shi, Wenhao Qi, Shihua Cao, Bingsheng Wang, Ruihan Xie, Jiani Yao, Xiajing Lou, Chaoqun Dong, Xiaohong Zhu, Danni He

    Published 2025-02-01
    “…Objectives Alzheimer’s disease (AD) poses a significant challenge for individuals aged 65 and older, being the most prevalent form of dementia. …”
    Get full text
    Article